Israel’s UroGen Pharma has three treatments for the treatment of cancers of the urinary system (bladder and kidneys). It has just raised $58.2 million on NASDAQ. UroGen’s MitoGel treatment for Upper Tract Urothelial Carcinoma has received Orphan status from the US FDA.
http://www.globes.co.il/en/article-urogen-pharma-raises-582m-in-nasdaq-ipo-1001187475
Pingback: Breakthrough treatment for urinary tract cancer - Israel Active